AB Science: towards a negative opinion from the EMA on mastinib for amyotrophic lateral sclerosis


(AOF) – AB Science announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a trend towards a negative opinion regarding the conditional marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following the Oral Explanation held at the CHMP meeting on May 28. The CHMP is expected to adopt a formal opinion on this marketing authorization application at its next meeting, which will take place from June 24 to 27, 2024.

AB Science announces that it will continue to work with the CHMP to determine how to proceed, including a possible request for review.

© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group

Did you like this article ? Share it with your friends using the buttons below.


Twitter


Facebook


Linkedin


E-mail





Source link -85